Edwards Lifesciences (EW) Revises FY25 Revenue Projection Upward

Edwards Lifesciences (EW) has updated its fiscal year 2025 financial outlook, projecting a revenue increase of 9% to 10% and showcasing strong financial health with robust margins. The company, a leader in medical devices specializing in structural heart disease treatments, provided this revised guidance at its annual investor conference. Despite positive analyst sentiment and strong financial indicators, a P/E ratio close to its 1-year high and recent insider selling activity suggest a mixed valuation picture.